HyperpigmentationNCT07900217
A Clinical Study to Assess the Effects of a Dark Spot Corrector on Dark Spots and Overall Complexion
A study testing Dark Spot Corrector Group in people with Hyperpigmentation and Dark Spots, run by Dime Beauty Co. at 1 site in United States.
Trial summary
This is a single-group, open-label, 90-day clinical study to assess the effectiveness of the Dark Spot Corrector by DIME Beauty on reducing the visibility of dark spots and improving overall complexion in females aged 50-65. Read more about this study
- Who is it for?
- Ages 50 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Hyperpigmentation, Dark Spots, Skin Complexion
- What is being tested?
- Dark Spot Corrector Group
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2024to 24 Jul 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Female
- Individuals aged 50-65
- Have visible dark spots on the face
- Willing to use only the Dark Spot Corrector for dark spots during the study period
- Willing to maintain the same skincare products and skincare routine for the duration of the study
- Has been using the same skincare regime for one month prior to study start
Show all 9Show fewer
- Generally healthy - do not live with any uncontrolled chronic disease
- Anyone willing to comply with the study requirements
- Anyone with no known allergies to any of the product ingredients
Who cannot join
- Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
- Anyone with known severe allergic reactions that require an Epi-Pen
- Anyone with known allergies to any of the test product ingredients
- Currently undergoing treatment for dark spots
- Women who are pregnant, breastfeeding, or trying to conceive
- Anyone unwilling to follow the study protocol
- Anyone currently participating or planning to participate in a research study
Trial locations and contacts
1 site in 1 country.
About this study
This is a single-group, open-label, 90-day clinical study to assess the effectiveness of the Dark Spot Corrector by DIME Beauty on reducing the visibility of dark spots and improving overall complexion in females aged 50-65. Thirty-five participants will apply 2 pumps of the product to their entire face twice daily (morning and night) after cleansing and toning.
Efficacy will be evaluated through subject-specific self-reported questionnaires administered at Baseline, Day 14, Day 30, Day 60, and Day 90, as well as expert skin grading and before-and-after photographs taken at Baseline, Day 30, Day 60, and Day 90. The study will also assess secondary outcomes including changes in skin brightness, smoothness, radiance, and evenness of complexion.
- Conditions
- Hyperpigmentation, Dark Spots, Skin Complexion
- Being tested
- Dark Spot Corrector Group
- Medical subject headings
- Hyperpigmentation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dark Spot Corrector GroupDietary supplement
All 35 participants apply 2 pumps of the Dark Spot Corrector by DIME Beauty to the entire face after cleansing and toning, both morning and night, for 90 days. No comparator arm is included.
| Study group | Role | What they receive |
|---|---|---|
| Dark Spot Corrector Group | Experimental | Not described Receives: Dietary Supplement: Dark Spot Corrector Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in dark spot visibility as assessed by self-reported questionnaire
Participant-reported reduction in the visibility of dark spots on the face, measured via subject-specific self-reported questionnaires
Measured: Baseline, Day 14, Day 30, Day 60, and Day 90
Change in dark spot visibility as assessed by expert skin grading of photographs
Expert-graded evaluation of dark spot visibility using standardized facial photographs (front, left, and right sides)
Measured: Baseline, Day 30, Day 60, and Day 90
Secondary outcomes (5)
Change in skin brightness
Participant-reported improvement in skin brightness assessed via subject-specific self-reported questionnaires
Measured: Baseline, Day 14, Day 30, Day 60, and Day 90
Change in skin smoothness
Participant-reported improvement in skin smoothness assessed via subject-specific self-reported questionnaires
Measured: Baseline, Day 14, Day 30, Day 60, and Day 90
Change in skin radiance
Participant-reported improvement in skin radiance assessed via subject-specific self-reported questionnaires
Measured: Baseline, Day 14, Day 30, Day 60, and Day 90
Change in evenness of complexion
Participant-reported improvement in evenness of complexion assessed via subject-specific self-reported questionnaires
Measured: Baseline, Day 14, Day 30, Day 60, and Day 90
Change in skin appearance as assessed by expert skin grading of photographs
Expert-graded evaluation of skin brightness, smoothness, radiance, and complexion evenness using standardized facial photographs
Measured: Baseline, Day 30, Day 60, and Day 90
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2026
- Study start1 Apr 2024
- Primary completion24 Jul 2024
- Study completion24 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HyperpigmentationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 35 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dime Beauty Co.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07900217
- Sponsor's protocol ID
- 20387
- Other IDs
- legacy-20387
- Status last verified
- Oct 2026
- First submitted
- 21 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study to Assess the Effects of a Dark Spot Corrector on Dark Spots and Overall Complexion
- ClinicalTrials.gov ID
- NCT07900217
- Acronym / sponsor ID
- 20387
- Conditions
- Hyperpigmentation, Dark Spots, Skin Complexion
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 35 participants (actual)
- Lead sponsor
- Dime Beauty Co.Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 1 Apr 2024 (actual)
- Primary completion
- 24 Jul 2024 (actual)
- Study completion
- 24 Jul 2024 (actual)
- First posted
- 28 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-group, open-label, 90-day clinical study to assess the effectiveness of the Dark Spot Corrector by DIME Beauty on reducing the visibility of dark spots and improving overall complexion in females aged 50-65. Thirty-five participants will apply 2 pumps of the product to their entire face twice daily (morning and night) after cleansing and toning.
Efficacy will be evaluated through subject-specific self-reported questionnaires administered at Baseline, Day 14, Day 30, Day 60, and Day 90, as well as expert skin grading and before-and-after photographs taken at Baseline, Day 30, Day 60, and Day 90. The study will also assess secondary outcomes including changes in skin brightness, smoothness, radiance, and evenness of complexion.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Dark Spot Corrector Group | Experimental | Dietary Supplement: Dark Spot Corrector Group |
Who may qualify
- Ages
- 50 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Female
- Individuals aged 50-65
- Have visible dark spots on the face
- Willing to use only the Dark Spot Corrector for dark spots during the study period
- Willing to maintain the same skincare products and skincare routine for the duration of the study
Key exclusion criteria (7 listed)
- Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
- Anyone with known severe allergic reactions that require an Epi-Pen
- Anyone with known allergies to any of the test product ingredients
- Currently undergoing treatment for dark spots
- Women who are pregnant, breastfeeding, or trying to conceive
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dark Spot Corrector GroupAll 35 participants apply 2 pumps of the Dark Spot Corrector by DIME Beauty to the entire face after cleansing and toning, both morning and night, for 90 days. No comparator arm is included. | Dietary supplement | Dark Spot Corrector Group |
Primary outcome
Change in dark spot visibility as assessed by self-reported questionnaire
Time frame: Baseline, Day 14, Day 30, Day 60, and Day 90
Participant-reported reduction in the visibility of dark spots on the face, measured via subject-specific self-reported questionnaires
Change in dark spot visibility as assessed by expert skin grading of photographs
Time frame: Baseline, Day 30, Day 60, and Day 90
Expert-graded evaluation of dark spot visibility using standardized facial photographs (front, left, and right sides)
5 secondary outcomes
Change in skin brightness
Time frame: Baseline, Day 14, Day 30, Day 60, and Day 90
Change in skin smoothness
Time frame: Baseline, Day 14, Day 30, Day 60, and Day 90
Change in skin radiance
Time frame: Baseline, Day 14, Day 30, Day 60, and Day 90
Change in evenness of complexion
Time frame: Baseline, Day 14, Day 30, Day 60, and Day 90
Change in skin appearance as assessed by expert skin grading of photographs
Time frame: Baseline, Day 30, Day 60, and Day 90
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
Related trials for Hyperpigmentation
RecruitingPhase 4
Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias
Telangiectasias, Reticular Veins
Not yet recruiting
Evaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation
Post-inflammatory Hyperpigmentation, Post-acne Hyperpigmentation
Not yet recruitingObservational study
Chinese Multicenter Registry for Peutz-Jeghers Syndrome
Peutz-Jeghers Syndrome
Enrolling by invitationPhase 4
Microneedling-Assisted Metformin, Tranexamic Acid, and Modified Kligman's Formula for Melasma
Melasma (Facial Melasma)
Active, not recruitingPhase 4
Efficacy and Safety of Triple-Combination Cream Plus Microneedling Along With Tranexamic Acid Versus Platelet-Rich Plasma in the Treatment of Moderate-to-Severe Melasma: A Randomized Comparative Study
Melasma (Facial Melasma)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dark Spot Corrector Group in people with Hyperpigmentation and Dark Spots, run by Dime Beauty Co. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in dark spot visibility as assessed by self-reported questionnaire (time frame: Baseline, Day 14, Day 30, Day 60, and Day 90). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.